Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor Combinations in Relapsed/Refractory Multiple Myeloma
NCT04941937Phase 2Recruiting
- Start
- Jan 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of selinexor in multiple myeloma (MM) (3 arms). Primary endpoint: Overall Response Rate at 12 months. Started Jan 2022; status: recruiting.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04941937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04941937.